Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: A retrospective analysis of 62 patients with psoriatic disease

Journal of Biological Regulators and Homeostatic Agents

Volumn 25, Issue 2, 2011, Pages 285-289

  Cassano, N ^a   Mastrandrea, V ^a   Principi, M ^a   Loconsole, F ^a   De Tullio, N ^a   Di Leo, A ^a   Vena, G A ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Adalimumab; Anti TNF biologicals; Etanercept; HBV occult carriers; Hepatitis B; Infliximab; Psoriasis

Indexed keywords

ADALIMUMAB; AMINOTRANSFERASE; EFALIZUMAB; ETANERCEPT; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; LAMIVUDINE; TUMOR NECROSIS FACTOR ANTIBODY; VIRUS DNA; ANTIBODY; ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; RNA DIRECTED DNA POLYMERASE INHIBITOR; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PSORIASIS; RETROSPECTIVE STUDY; VIRUS ACTIVATION; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; HETEROZYGOTE; IMMUNOLOGY; LETTER; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; VIRUS LATENCY;

HEPATITIS B VIRUS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES; ANTIBODIES, MONOCLONAL; CARRIER STATE; DRUG COMBINATIONS; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULIN G; LAMIVUDINE; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA; VIRUS LATENCY;

EID: 80052896047     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006; 20:757-90.
2. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006; 2:1366-71.
3. Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 2007; 37:705-12.
4. Marzano A, Angelucci E, Andreone P, et al.; Italian Association for the Study of the Liver. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39:397-408.
5. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49(S):156-65.
6. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46:160-70.
7. Robinson H, Walker-Bone K. Anti-TNF-alpha therapy for rheumatoid arthritis among patients with chronic hepatitis B infection. Rheumatology (Oxford) 2009; 48:448-50.
8. Wendling D, Di Martino V, Prati C, Toussirot E, Herbein G. Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy. Joint Bone Spine 2009; 76:308-11.
9. Chung SJ, Kim JK, Park MC, Park YB, Lee SK. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol 2009; 36:2416-20.
10. Shale MJ, Seow CH, Coffin CS, Kaplan GG, Panaccione R, Ghosh S. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31:20-34.
11. Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007; 13:508-9.
12. Montiel PM, Solis JA, Chirinos JA, a Casis B, Sánchez F, Rodríguez S. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008; 28:718-20.
13. Charpin C, Guis S, Colson P, et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 2009; 11:R179.
14. Nosotti L, Francesconi F, Izzi S, Berardesca E, Morrone A, Bonifati C. Safety of antirumour necrosis factor-alpha therapy in psoriatic patients with hepatitis B virus infection. Br J Dermatol 2010; 162:1408-10.
15. Kim YJ, Bae SC, Sung YK, Kim TH, Jun JB, Yoo DH, Kim TY, Sohn JH, Lee HS. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. J Rheumatol 2010; 37:346-50.
16. Carroll MB, Bond MI. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2008; 38:208-17.
17. Altomare G, Ayala F, Berardesca E, et al. Etanercept provides a more physiological approach in the treatment of psoriasis. Dermatol Ther 2008; (S):1-14.